{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Liu W"],"funding":["the Jiangsu Provincial Natural Science Foundation","the Beijing Bethune Medical Science Research Foundation","the Discipline Co-construction Project of Pediatrics and Immunology","the Clinical Research and Cultivation Program of the Second Affiliated Hospital of Anhui Medical University","the Discipline Co-construction Project of Pediatrics and Physiology","the Scientific Research Foundation of Anhui Medical University","the Health Research Program of Anhui"],"pagination":["985-999"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11836086"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["480(2)"],"pubmed_abstract":["Acute myeloid leukemia (AML) is a rare and heterogeneous disease. Over the past few decades, patient prognosis has improved with continuous improvements in treatment, but outcomes for some patients with primary drug resistance or relapse after treatment remain poor. Additional therapies to improve outcomes for these patients are urgently needed. FYB1 expression differs substantially between AML tissues and normal tissues. High FYB1 expression is correlated with poorer overall survival (OS), indicating that FYB1 may regulate AML progression. Therefore, understanding the effect of FYB1 on AML could improve the success rate of therapeutic approaches and prognosis for patients with AML. In this study, through analysis of large databases and both in vivo and in vitro experiments, we assessed th"],"journal":["Molecular and cellular biochemistry"],"pubmed_title":["FYB1-targeted modulation of CAPG promotes AML progression."],"pmcid":["PMC11836086"],"funding_grant_id":["(No. 2021xkj168)","(No. 2021LCXK030)","(No. 2020LCXK017)","(No. SCE128EN)","(No. 2020LCYSOCS304)","(No. AHWJ2022c006)","(BK20230217)"],"pubmed_authors":["Yang L","Zhang K","Wei A","Xie Z","Fang F","Huang L","Cai H","Cheng Y","Liu W","Yin H","Wu Z","Wang N","Pan J","Tu S","Hong Y","Tian X","Chu J","Liu C"],"additional_accession":[]},"is_claimable":false,"name":"FYB1-targeted modulation of CAPG promotes AML progression.","description":"Acute myeloid leukemia (AML) is a rare and heterogeneous disease. Over the past few decades, patient prognosis has improved with continuous improvements in treatment, but outcomes for some patients with primary drug resistance or relapse after treatment remain poor. Additional therapies to improve outcomes for these patients are urgently needed. FYB1 expression differs substantially between AML tissues and normal tissues. High FYB1 expression is correlated with poorer overall survival (OS), indicating that FYB1 may regulate AML progression. Therefore, understanding the effect of FYB1 on AML could improve the success rate of therapeutic approaches and prognosis for patients with AML. In this study, through analysis of large databases and both in vivo and in vitro experiments, we assessed th","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Feb","modification":"2026-06-01T20:08:41.603Z","creation":"2025-04-07T07:50:47.49Z"},"accession":"S-EPMC11836086","cross_references":{"pubmed":["38700746"],"doi":["10.1007/s11010-024-04992-4"]}}